Noble Clinical Research | Tucson, AZ

Research site

(Unclaimed)

Location

2055 W Hospital Drive Suite 145, Tucson, Arizona, United States of America

Site insights

Top conditions

Top treatments

TAK-279

FX006

CNTX-4975-05

Vibegron

ACT-541468

Daridorexant

Tanezumab

Elagolix

GRT7039

SAR440340

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

15 of 43 total trials

A Phase 2 Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine

The goal of this clinical trial is to assess the safety and immunogenicity of an srRNA-based vaccine, JCXH-105, in the prevention of Herpes Zoster (S...

Not yet enrolling

Herpes Zoster (HZ)

Shingles

Biological: Shingrix

Biological: JCXH-105

A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

a Phase 2 trial to evaluate the blood pressure-lowering effect of lorundrostat (an aldosterone synthase inhibitor), administered on a background of a...

Enrolling

Hypertension

Drug: Placebo

Drug: lorundrostat Dose 2

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque p...

Active, not recruiting

Plaque Psoriasis

Drug: TAK-279

Drug: Placebo

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Adults

The purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy adults (18 to 55 years of age).

Active, not recruiting

Epstein-Barr Virus Infection

Biological: Placebo

Biological: mRNA-1195.2

A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant (VENTURA-7)

The purpose of this study is to evaluate how well aticaprant works as compared with placebo when given along with an antidepressant therapy in improv...

Enrolling

Anhedonia

Depressive Disorder, Major

Drug: Aticaprant

Other: Placebo

A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19 (NextCOVE)

The purpose of this study (Part 1 and Part 2) is to evaluate the relative vaccine efficacy (rVE), safety, reactogenicity, and immunogenicity of mRNA-...

Active, not recruiting

COVID-19

Biological: mRNA-1283.222

Biological: mRNA-1273.815

A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes

The purpose of this study is to generate safety and immunogenicity data and establish a proof-of-concept of clinical benefit of the mRNA-1608 vaccine...

Active, not recruiting

Genital Herpes

Biological: BEXSERO

Biological: mRNA-1608

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoria...

Enrolling

Plaque Psoriasis

Drug: TAK-279

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

The main purpose of this study is to evaluate the efficacy of mRNA 1647 vaccine in CMV-seronegative female participants and to evaluate the safety an...

Active, not recruiting

Cytomegalovirus Infection

Biological: mRNA-1647

Biological: Placebo

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects with Non-segmental Vitiligo.

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of VYN201 Gel in subjects with non-segmental vitiligo.

Enrolling

Non-segmental Vitiligo

Drug: Vehicle Gel

Drug: VYN201 Gel

A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD (AERIFY-4)

This is a parallel, double blind, Phase 3, 2-arm study that is designed to provide additional safety information, assess the durability of treatment...

Enrolling

Chronic Obstructive Pulmonary Disease

Drug: Placebo

Drug: Itepekimab (SAR440340)

Comparison of a Single RTX-GRT7039 and Placebo Intra-articular Injection for Pain Associated With Osteoarthritis of the Knee

A double-blind, randomized, placebo-controlled, parallel-group, multi-site, clinical trial to confirm the efficacy and safety of single injection of...

Active, not recruiting

Osteoarthritis

Drug: RTX-GRT7039

Drug: Placebo

Parallel-Arm Study to Compare AD109 to Placebo with Patients with OSA (SynAIRgy Study)

This is a Phase 3 Randomized Double-Blind Placebo-Controlled 6-month Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Ob...

Active, not recruiting

OSA

Drug: Placebo

Drug: AD109

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-1)

Primary Objective:Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in...

Active, not recruiting

Chronic Obstructive Pulmonary Disease

Drug: Placebo

Drug: Itepekimab SAR440340

Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. (RENOIR)

Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a...

Enrolling

Lower Respiratory Tract Illness

Biological: RSVpreF

Biological: Placebo